Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006

Arthritis and Rheumatism

Volumn 63, Issue 6, 2011, Pages 1681-1688

  Costenbader, Karen H ^a   Desai, Amrita ^b   Alarcón, Graciela S ^c   Hiraki, Linda T ^a   Shaykevich, Tamara ^a   Brookhart, M Alan ^d   Massarotti, Elena ^a   Lu, Bing ^a   Solomon, Daniel H ^a   Winkelmayer, Wolfgang C ^e  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN;

ADULT; AFRICAN AMERICAN; ARTICLE; BODY MASS; CLINICAL FEATURE; CREATININE BLOOD LEVEL; DEMOGRAPHY; DIABETES MELLITUS; FEMALE; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MORTALITY; ONSET AGE; PERITONEAL DIALYSIS; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; COMORBIDITY; DIABETES MELLITUS; FEMALE; HUMANS; HYPERTENSION; INCIDENCE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PREVALENCE; RENAL DIALYSIS; SEX FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 79958029462     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30293     Document Type: Article

References (35)

1. Carreno L, Lopez-Longo FJ, Monteagudo I, Rodriguez-Mahou M, Bascones M, Gonzalez CM, et al. Immunological and clinical differences between juvenile and adult onset of systemic lupus erythematosus. Lupus 1999; 8: 287-92. (Pubitemid 29292093)
2. Tucker LB, Menon S, Schaller JG, Isenberg DA,. Adult- and childhood-onset systemic lupus erythematosus: a comparison of onset, clinical features, serology, and outcome. Br J Rheumatol 1995; 34: 866-72.
3. Huong DL, Papo T, Beaufils H, Wechsler B, Bletry O, Baumelou A, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore) 1999; 78: 148-66. (Pubitemid 29231142)
4. Adler M, Chambers S, Edwards C, Neild G, Isenberg D,. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford) 2006; 45: 1144-7. (Pubitemid 44542106)
5. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al, European Working Party on Systemic Lupus Erythematosus. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308. (Pubitemid 37229465)
6. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D,. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med 1987; 83: 877-85. (Pubitemid 18098162)
7. Cameron JS,. Lupus nephritis. J Am Soc Nephrol 1999; 10: 413-24. (Pubitemid 29068083)
8. Danila MI, Pons-Estel GJ, Zhang J, Vila LM, Reveille JD, Alarcon GS,. Renal damage is the most important predictor of mortality within the damage index: data from LUMINA LXIV, a multiethnic US cohort. Rheumatology (Oxford) 2009; 48: 542-5.
9. Danieli MG, Palmieri C, Salvi A, Refe MC, Strusi AS, Danieli G,. Synchronised therapy and high-dose cyclophosphamide in proliferative lupus nephritis. J Clin Apher 2002; 17: 72-7. (Pubitemid 34809554)
10. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219-28. (Pubitemid 41697285)
11. Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002; 46: 2121-31.
12. Ioannidis JP, Boki KA, Katsorida ME, Drosos AA, Skopouli FN, Boletis JN, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000; 57: 258-64. (Pubitemid 30227773)
13. Mok CC, Ho CT, Chan KW, Lau CS, Wong RW,. Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002; 46: 1003-13. (Pubitemid 34303813)
14. Ward MM,. Changes in the incidence of end-stage renal disease due to lupus nephritis, 1982-1995. Arch Intern Med 2000; 160: 3136-40.
15. Ward MM,. Changes in the incidence of endstage renal disease due to lupus nephritis in the United States, 1996-2004. J Rheumatol 2009; 36: 63-7.
16. Advisory Committee to the Renal Transplant Registry. Renal transplantation in congenital and metabolic diseases: a report from the ASC/NIH Renal Transplant Registry. JAMA 1975; 232: 148-53.
17. Ponticelli C, Moroni G,. Renal transplantation in lupus nephritis. Lupus 2005; 14: 95-8. (Pubitemid 40216076)
18. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S,. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995; 333: 333-6.
19. Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, Wang Z, Baird B, Barenbaum L, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005; 20: 167-75. (Pubitemid 40207623)
20. Meier-Kriesche HU, Port FK, Ojo AO, Rudich SM, Hanson JA, Cibrik DM, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311-7.
21. Clark WF, Jevnikar AM,. Renal transplantation for end-stage renal disease caused by systemic lupus erythematosus nephritis. Semin Nephrol 1999; 19: 77-85. (Pubitemid 29048848)
22. US Renal Data System. Researcher's guide to the USRDS database. Bethesda (MD): NIH, National Institute of Diabetes and Digestive and Kidney Diseases; 2006.
23. US Census Bureau. Population estimates. URL:.
24. US Census Bureau. Census regions and divisions of the United States. URL:.
25. Tang H, Chelamcharla M, Baird BC, Shihab FS, Koford JK, Goldfarb-Rumyantzev AS,. Factors affecting kidney-transplant outcome in recipients with lupus nephritis. Clin Transplant 2008; 22: 263-72. (Pubitemid 351689656)
26. Coladonato JA, Frankenfield DL, Reddan DN, Klassen PS, Szczech LA, Johnson CA, et al. Trends in anemia management among US hemodialysis patients. J Am Soc Nephrol 2002; 13: 1288-95. (Pubitemid 34441410)
27. Winkelmayer WC,. Confusion about the appropriate use of erythropoiesis-stimulating agents in patients undergoing maintenance dialysis. Semin Dial 2010; 23: 486-91.
28. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum 2008; 58: 15-25.
29. Wang V, Lee SY, Patel UD, Weiner BJ, Ricketts TC, Weinberger M,. Geographic and temporal trends in peritoneal dialysis services in the United States between 1995 and 2003. Am J Kidney Dis 2010; 55: 1079-87.
30. Burkart J,. The future of peritoneal dialysis in the United States: optimizing its use. Clin J Am Soc Nephrol 2009; 4 Suppl 1: S125-31.
31. Federal Register. Vol. 75, No. 155. Aug 12, 2010. Proposed rules. Department of Health and Human Services (US), Centers for Medicare & Medicaid Services, 42 CFR Part 413. URL:.
32. Ward MM,. Access to renal transplantation among patients with end-stage renal disease due to lupus nephritis. Am J Kidney Dis 2000; 35: 915-22. (Pubitemid 30238205)
33. Longenecker JC, Coresh J, Klag MJ, Levey AS, Martin AA, Fink NE, et al, for the CHOICE study. Validation of comorbid conditions on the end-stage renal disease medical evidence report: the CHOICE study. J Am Soc Nephrol 2000; 11: 520-9. (Pubitemid 30115082)
34. Ashby VB, Kalbfleisch JD, Wolfe RA, Lin MJ, Port FK, Leichtman AB,. Geographic variability in access to primary kidney transplantation in the United States, 1996-2005. Am J Transplant 2007; 7: 1412-23. (Pubitemid 46606944)
35. Burgos PI, Perkins EL, Pons-Estel GJ, Kendrick SA, Liu JM, Kendrick WT, et al. Risk factors and impact of recurrent lupus nephritis in patients with systemic lupus erythematosus undergoing renal transplantation: data from a single US institution. Arthritis Rheum 2009; 60: 2757-66.